SXTC
Income statement / Annual
Last year (2024), China SXT Pharmaceuticals, Inc.'s total revenue was $1.93 M,
a decrease of 2.19% from the previous year.
In 2024, China SXT Pharmaceuticals, Inc.'s net income was -$3.10 M.
See China SXT Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
03/31/2024 |
03/31/2023 |
03/31/2022 |
03/31/2021 |
03/31/2020 |
03/31/2019 |
03/31/2018 |
03/31/2017 |
03/31/2016 |
| Operating Revenue |
$1.93 M
|
$1.97 M
|
$2.60 M
|
$4.78 M
|
$5.16 M
|
$7.01 M
|
$7.02 M
|
$4.88 M
|
$3.72 M
|
| Cost of Revenue |
$1.37 M |
$1.55 M |
$1.35 M |
$1.94 M |
$2.46 M |
$2.40 M |
$3.62 M |
$2.57 M |
$2.92 M |
| Gross Profit |
$553,971.00 |
$426,271.00 |
$1.25 M |
$2.84 M |
$2.70 M |
$4.61 M |
$3.40 M |
$2.31 M |
$793,988.00 |
| Gross Profit Ratio |
0.29 |
0.22 |
0.48 |
0.59 |
0.52 |
0.66 |
0.48 |
0.47 |
0.21 |
| Research and Development
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative
Expenses |
$2.64 M
|
$5.65 M
|
$5.52 M
|
$3.45 M
|
$2.46 M
|
$1.24 M
|
$1.26 M
|
$565,455.00
|
$433,819.00
|
| Selling & Marketing
Expenses |
$433,566.00
|
$387,452.00
|
$924,538.00
|
$1.59 M
|
$1.58 M
|
$1.61 M
|
$512,482.00
|
$144,364.00
|
$151,028.00
|
| Selling, General &
Administrative Expenses |
$3.07 M
|
$6.03 M
|
$6.44 M
|
$5.04 M
|
$4.04 M
|
$2.84 M
|
$1.77 M
|
$709,819.00
|
$584,847.00
|
| Other Expenses |
$0.00 |
$149,513.00 |
-$181,581.00 |
$871,650.00 |
-$73,771.00 |
$27,141.00 |
-$3,803.00 |
$18,403.00 |
$0.00 |
| Operating Expenses |
$3.07 M |
$6.03 M |
$6.44 M |
$5.04 M |
$4.04 M |
$2.84 M |
$1.77 M |
$709,819.00 |
$584,847.00 |
| Cost And Expenses |
$4.44 M |
$7.58 M |
$7.79 M |
$6.97 M |
$6.50 M |
$5.24 M |
$5.39 M |
$3.28 M |
$3.51 M |
| Interest Income |
$0.00 |
$476,776.00 |
$36,695.00 |
$1.11 M |
$3.35 M |
$5,174.00 |
$0.00 |
$0.00 |
$51,059.00 |
| Interest Expense |
$544,279.00 |
$476,776.00 |
$218,276.00 |
$1.62 M |
$3.35 M |
$5,174.00 |
$779.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$203,247.00
|
$250,162.00
|
$320,007.00
|
$345,414.00
|
$331,837.00
|
$180,917.00
|
$129,439.00
|
$99,228.00
|
$88,964.00
|
| EBITDA |
-$2.35 M
|
-$5.21 M
|
-$5.05 M
|
-$1.85 M
|
-$1.01 M
|
$1.95 M
|
$1.76 M
|
$1.70 M
|
$298,105.00
|
| EBITDA Ratio |
-1.22 |
-2.72 |
-1.87 |
-0.39 |
0.89 |
0.28 |
0.25 |
0.35 |
0.08 |
| Operating Income Ratio
|
-1.3
|
-2.84
|
-1.99
|
-0.46
|
0.83
|
0.25
|
0.23
|
0.33
|
0.06
|
| Total Other
Income/Expenses Net |
-$583,315.00
|
-$327,263.00
|
-$218,276.00
|
-$743,790.00
|
-$9.05 M
|
$21,967.00
|
-$4,582.00
|
-$21,987.00
|
-$20,415.00
|
| Income Before Tax |
-$3.10 M |
-$5.93 M |
-$5.41 M |
-$2.94 M |
-$10.39 M |
$1.79 M |
$1.63 M |
$1.58 M |
$188,725.00 |
| Income Before Tax Ratio
|
-1.61
|
-3.01
|
-2.08
|
-0.62
|
-2.01
|
0.26
|
0.23
|
0.32
|
0.05
|
| Income Tax Expense |
$0.00 |
$476,776.00 |
$328,146.00 |
-$192,683.00 |
-$101,722.00 |
$252,232.00 |
$440,103.00 |
$395,049.00 |
$47,181.00 |
| Net Income |
-$3.10 M |
-$5.93 M |
-$5.74 M |
-$2.75 M |
-$10.29 M |
$1.54 M |
$1.19 M |
$1.19 M |
$141,544.00 |
| Net Income Ratio |
-1.61 |
-3.01 |
-2.2 |
-0.58 |
-1.99 |
0.22 |
0.17 |
0.24 |
0.04 |
| EPS |
-3.57 |
-22.23 |
-137.92 |
-95.48 |
-832.08 |
149.67 |
0 |
0 |
0 |
| EPS Diluted |
-3.57 |
-22.23 |
-137.92 |
-95.48 |
-832.08 |
149.67 |
0 |
0 |
0 |
| Weighted Average Shares
Out |
$867,422.00
|
$266,973.00
|
$41,591.00
|
$28,782.00
|
$12,364.00
|
$10,284.00
|
$0.00
|
$0.00
|
$0.00
|
| Weighted Average Shares
Out Diluted |
$867,422.00
|
$266,973.00
|
$41,591.00
|
$28,782.00
|
$12,364.00
|
$10,284.00
|
$0.00
|
$0.00
|
$0.00
|
| Link |
|
|
|
|
|
|
|
|
|
